NASHVILLE, Tenn., July 24, 2018 /PRNewswire/ -- IQuity, a Nashville-based data analytics company that specializes in predicting, detecting and monitoring chronic disease, today announced the launch of a revolutionary analytics platform to apply this approach within large populations. Company officials also announced that two former senior executives of healthcare technology company WPC Healthcare/Intermedix have been named advisors and will assist in the further development of the new platform.
This new platform represents IQuity's evolution from a developer of genomic diagnostic technologies to an integrated data science company that analyzes many types of public and private data sets to provide new insights into the health of populations.
IQuity's new technology holds the promise of enhancing outcomes while lowering the cost of healthcare and is likely to appeal to organizations responsible for the healthcare of many people, such as self-insured employers, benefit managers, health insurance companies, pharmaceutical firms and care management companies.
The approach was demonstrated in a pilot study that analyzed healthcare claims for 20 million people in New York – comprising four billion data points. Focusing on multiple sclerosis (MS), the approach predicted with over 90 percent accuracy the onset of MS within that population at least eight months before traditional methods would typically yield a diagnosis. Early diagnosis can lead to better patient outcomes and deliver substantial savings, as spending on healthcare tends to accelerate prior to a definite diagnosis. The approach can be applied to any disease.
"Our work with machine learning started over eight years ago. Recent advances in our computational abilities and machine learning methods have allowed us to look at large datasets to derive insights. Our first application combed through genomic data to create diagnostic tools for providers. Our new platform extends our experience and knowledge of data science and chronic disease to inform interventions across the healthcare continuum," said Dr. Chase Spurlock, IQuity CEO.
IQuity has named Ray Guzman and Damian Mingle as advisors for technology. Both previously worked at healthcare data analytics company WPC Healthcare as CEO and Chief Data Scientist, respectively. As part of the leadership team at WPC, they participated in facilitating WPC's acquisition by Intermedix.
"I am excited to advise IQuity as it builds on its groundbreaking machine learning work in genomics to create technology that analyzes healthcare data across an entire population. The predictive and prescriptive possibilities of this approach can transform how healthcare is provided and paid for," said Guzman.
"The work IQuity has accomplished in this area to date is impressive and the new platform holds the potential to revolutionize the way diseases are detected and monitored," said Mingle.
IQuity, Inc. is a data analytics company pioneering the use of machine learning models across genomic and population level datasets to predict, detect, and monitor chronic disease. We are leading the way with technology that synthesizes and analyzes multiple datasets not easily accessed or interpreted by healthcare stakeholders. The result is actionable information to detect disease earlier, treat more effectively, improve outcomes, and lower costs. For more information, visit iquity.com and find IQuity on Facebook and Twitter at @iquityinc.
CONTACT: Leanna Bernhard, 615-515-4896, [email protected]
SOURCE IQuity, Inc.